← Back to patent-cliff list
Onvuzosiran
Tier C — Watch / tradeOnvuzosiran
ADARx Pharmaceuticals Inc
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Nucleic acid drug
Type
Targets：KLKB1
Indications (approved)：遗传性血管性水肿
Regional status
US
Phase III
2025-08-28
EU
Phase III
2025-08-28
China
Phase III
2025-08-28
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Onvuzosiran?
Approved indications include: 遗传性血管性水肿.
When does the Onvuzosiran patent expire?
No public expiry year is available for Onvuzosiran yet; this page updates once verified.
How do I get a quote for Onvuzosiran intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-30